As Gilead Seeks New CEO, Second Quarter Shows Stability
Yescarta continued its growth trajectory, the HIV franchise showed solid sales growth and the hepatitis C franchise stayed steady – plus Gilead could jump to the head of the line in NASH.
You may also be interested in...
Akcea Expects Convenience Edge For Tegsedi, Despite Monitoring Requirements
Approved two months after Alnylam’s Onpattro, Tegsedi is priced almost identically in the same hATTR indication. Ionis affiliate Akcea hopes weekly subcutaneous administration will provide convenience benefit compared to I.V. Onpattro.
Gilead And Novartis Unveil EU Marketing Plans For CAR-T Therapies, But Hurdles Remain
Building manufacturing capacity, educating physicians, and reaching agreements with pricing and reimbursement bodies are just some of the hurdles CAR-T therapies have to jump over in Europe, following their approval by the EU Commission earlier this week.
AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.